Benutzerspezifische Werkzeuge

Solide Tumoren

Diverse: ACT Immatics IMA 202-101

Phase 1 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients with recurrent and/or refractory solid Tumors.Mehr…

Diverse: EMR 100036-002

First in man study with MEN1112, a CD157 targeted monoclonal antibody, in relapsed or refractory Acute Myeloid LeukemiaMehr…

Diverse: Merck MK 4280-001

A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors.Mehr…

Glioblastom: AMG 596

Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 in Subjects With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII).Mehr…

Diverse: MSD MK4621-002

A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of MK-4621/JetPEI as Monotherapy or in Combination with Pembrolizumab (MK-3475) in Participants with advanced/Metastatic or Recurrent Solid Tumors.Mehr…